About Algeta
Algeta is a Healthcare company based in Oslo (Norway) founded in 1997, and was acquired by Bayer in December 2013. Alpha-emitting pharmaceuticals are developed for cancer treatment. Algeta has raised $29 million across 1 funding round from investors including Bayer, Selvaag and SR One. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is ALGETA AS.
Company details
Algeta was founded in 1997 in Oslo, Norway, as an oncology-focused company. Targeted therapies based on an alpha-pharmaceutical platform were developed for cancer patients. The lead product, radium-223 dichloride, was advanced through Phase III trials for castration-resistant prostate cancer with bone metastases. Thorium-227 conjugates linked to tumor-targeting molecules were explored in preclinical stages. Acquisition by Bayer occurred in December 2013.
- Headquarters Oslo, Norway
- Stage Acquired
- SectorsHealthcare
- Website algeta.com
- Social LinkedIn
- Acquired by Bayer (Dec 2013)
- Legal Name Algeta As
Funding Insights of Algeta
Algeta has successfully raised a total of $29M through 1 strategic funding round. The most recent funding activity was a Series A round of $29 million completed in September 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29M
- Total Rounds 1
- Last Round Series A — $29M
- First Round $29M
(Sep 2005)
- Investors Count 4
All 1 funding rounds of Algeta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
5 investors in total: 5 institutional.
Investors in Algeta
Algeta has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Bayer, Selvaag and SR One.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| selvaag.no | ||||
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Wealth management and investment services are provided by NorgesInvestor. | norgesinvestor.no | Norway | ||
| healthcap.eu | ||||
Life science solutions for healthcare and agriculture are delivered. | 1863 | bayer.com | Leverkusen, Germany |
Investor details for Algeta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Algeta
3 dated milestones of Algeta across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Algeta is founded.
- Funding First funding round of $29.0M.
- Exit Acquired by Bayer.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Algeta
Complete news archive for Algeta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Algeta
Algeta was founded in 1997 and raised its 1st funding round 8 years after it was founded.
Algeta is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.
Algeta is a funded company, having raised a total of $29M across 1 funding round to date. The company's 1st funding round was a Series A of $29M, raised on Sep 2005.
Algeta was founded in 1997 in Oslo, Norway, as an oncology-focused company. Targeted therapies based on an alpha-pharmaceutical platform were developed for cancer patients. The lead product, radium-223 dichloride, was advanced through Phase III trials for castration-resistant prostate cancer with bone metastases. Thorium-227 conjugates linked to tumor-targeting molecules were explored in preclinical stages. Acquisition by Bayer occurred in December 2013.
Algeta has 5 investors. Key investors include Bayer, Selvaag, SR One, NorgesInvestor, and Healthcap.
Algeta operates through Algeta As.
Yes. Algeta was acquired by Bayer in December 2013.